Shop Now Contact

Anti-Human IgE (Omalizumab Biosimilar)

Cat # Size Price Quantity
5044011 mg$175
5044025 mg$590
50440320 mg$1800

  Bulk/Custom

Product Details

CloneOmalizumab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionOmalizumab Biosimilar, Human IgE Monoclonal Antibody
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman IgE
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
Maximal Shelf Life12 months
Target NameIgE, Immunoglobulin E
Antibody TypeRecombinant
Research AreasAllergy, Infectious Diseases, Mast cells, Basophils, Monocytes, Dendritic cells
See All FormatsClone Omalizumab

Background Information

Omalizumab is a recombinant humanized monoclonal antibody that belongs to the immunoglobulin G1 kappa (IgG1κ) subclass. It was engineered to specifically bind to human immunoglobulin E (IgE), the antibody class central to allergic responses. Structurally, Omalizumab is a glycoprotein with a molecular weight of approximately 149 kilodaltons (kDa), composed of two identical heavy chains and two identical light chains linked by disulfide bonds to form the canonical Y-shaped configuration characteristic of IgG antibodies. The molecule is expressed in mammalian cell systems, such as Chinese Hamster Ovary (CHO) cells, to ensure proper protein folding, glycosylation, and structural stability compatible with human antibodies.

The antigen-binding fragments (Fab) contain variable heavy (VH) and variable light (VL) domains that include complementarity-determining regions (CDRs). These CDRs form the paratope responsible for the high-affinity recognition of a specific epitope located within the Cε3 domain of the Fc portion of free IgE. This binding site is distinct from the IgE region that interacts with the high-affinity FcεRI receptor on mast cells and basophils. By binding to circulating IgE, Omalizumab forms immune complexes that reduce available free IgE levels and prevent IgE from attaching to FcεRI and FcεRII (CD23) receptors. In experimental systems, this results in downregulation of FcεRI expression and diminished IgE-mediated signaling, which includes the inhibition of receptor crosslinking and subsequent intracellular calcium mobilization and mediator release.

The Fc (fragment crystallizable) region of Omalizumab is derived from human IgG1 and primarily provides structural integrity and extended half-life through neonatal Fc receptor (FcRn) recycling. Unlike many IgG1 antibodies, it exhibits minimal effector functions such as complement activation or antibody-dependent cellular cytotoxicity (ADCC). Overall, Omalizumab exemplifies precision antibody design, combining specific antigen neutralization with structural and pharmacokinetic stability to selectively modulate IgE-mediated pathways in immunological research.

Data Sheets

Anti-Human IgE (Omalizumab Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.